

## Anti-EGFR Antibody (Nimotuzumab)

### Introduction

Nimotuzumab is a humanized monoclonal antibody mainly used to treat head and neck squamous cell carcinoma and other solid tumors. It inhibits the proliferation and survival of tumor cells by targeting the epidermal growth factor receptor (EGFR) and blocking its signal transduction. Nimotuzumab is derived from combining the constant region of human antibodies with the variable region of mouse antibodies through genetic engineering technology. Its composition includes antibody molecules of the IgG1 subtype, which can specifically bind to and neutralize EGFR, interfering with the growth signal pathway of tumor cells.

### Product parameters

Alternative Names	Theraloc, h-R3
Target Accession	-
Target	EGFR
CAS number	780758-10-3
Molecular Weight	-
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	1 mg/mL
Buffer System	100 mM Pro 20 mM Arg pH 5.0.
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years

## Note

1. This product is for scientific research use only.



### APEx BIO Technology

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

